Metabolic
Semaglutide
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the US and EU.
Quick start
Semaglutide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 0.25–2.4 mg per administration
- How often
- Once a week
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Timing
- Once weekly on the same day; time of day is flexible.
- What people report
- Appetite changes are often noticed within the first weeks; dose is escalated slowly.
- Time to steady level
- ~35.0 days — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
- Cycle length
- titrated over months
- Break between
- n/a — titrated, not cycled Why
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Key properties
Molecular reference data.
- Formula
- C187H291N45O59
- Mol. weight
- 4,113.64 Da
- CAS
- 910463-68-2
- PubChem CID
- 56843331
External references
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Semaglutide describe 0.25–2.4 mg per administration. Descriptive only, not a recommendation.
Dosing schedule
How Semaglutide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Weeks 1–4Starting step to limit gastrointestinal effects; not intended for a glucose effect yet. | 0.25 mg | Once weekly | SubQ |
| Weeks 5–8 | 0.5 mg | Once weekly | SubQ |
| Weeks 9–12 | 1 mg | Once weekly | SubQ |
| Weeks 13–16 | 1.7 mg | Once weekly | SubQ |
| Week 17+Highest commonly-reported step; step up no sooner than every 4 weeks and only as tolerated. | 2.4 mg | Once weekly | SubQ |
What it can be combined with
How Semaglutide is commonly discussed alongside other peptides and drugs.
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.
- RetatrutideBoth drive GLP-1 receptor agonism, so running them together doubles the same mechanism rather than adding a new one.Avoid combination
- TirzepatideTwo incretin agonists on the same receptor — the combination adds gastrointestinal effects, not benefit, in research reports.Avoid combination
- CagrilintideThe CagriSema pairing is studied, but the two together intensify gastrointestinal effects — escalate slowly.Use caution
- InsulinAdditive glucose-lowering raises the hypoglycemia signal; glucose bears closer monitoring when combined.Monitor combination
- Oral medicationsSlowed gastric emptying can alter oral-drug absorption — a known caution for oral contraceptives in particular.Requires timing
- BPC-157Different mechanisms; BPC-157 is commonly discussed for gastrointestinal comfort during GLP-1 use, with no adverse interaction reported.Commonly combined
- MetforminFrequently co-administered in studies with no adverse interaction reported.Commonly combined
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.98× single dose
- Time to steady state
- 35.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- STEP 1 (Wilding et al., NEJM 2021)Weekly semaglutide escalated to 2.4 mg over 16 weeks in obesity research.